newsfieldsarchivecontact ussupport
landingconversationsabout usarticles

Regenx Announces Non-Brokered Financing for Gross Proceeds of $230,833

April 1, 2026 - 17:16

Regenx Announces Non-Brokered Financing for Gross Proceeds of $230,833

Regenx Tech Corp. has successfully closed a non-brokered financing round, raising gross proceeds of $230,833. The capital was secured through the issuance of unsecured debentures.

The newly issued debentures carry a significant annual interest rate of 25 percent. According to the terms, the company retains the right to redeem the debentures at any time, provided it gives a 10-day prior written notice to the holders.

Management has stated that the incoming funds are earmarked for essential corporate purposes. The primary use of the proceeds will be to support ongoing operational needs and general working capital requirements. This financing move is positioned as a strategic step to bolster the company's financial position and ensure the continuity of its business activities.

The completion of this financing provides Regenx with immediate capital to advance its corporate strategy without engaging a brokerage firm, allowing for a direct and expedited transaction. The company's leadership views this as a crucial infusion of capital to maintain momentum and execute its planned operational objectives in the coming period.


MORE NEWS

Burry Observes Strong Demand for NVDA Stock Amid Concerns

November 13, 2026 - 07:24

Burry Observes Strong Demand for NVDA Stock Amid Concerns

Michael Burry noted a `mechanical bid` that surged at the opening of trading on Thursday, suggesting that fund flows and established investment rules were overpowering sellers. This phenomenon...

Codexis Reports Third Quarter Loss

November 12, 2026 - 21:40

Codexis Reports Third Quarter Loss

Codexis announced its financial results for the third quarter, revealing a loss of 8 cents per share. The Redwood City, California-based biotechnology firm faced challenges during this period,...

Is Now the Right Time to Invest in Halozyme Stock?

November 12, 2026 - 01:35

Is Now the Right Time to Invest in Halozyme Stock?

Investors are closely watching Halozyme Therapeutics as potential opportunities arise in the biotech sector. With a recent surge in interest, many are wondering if now is the time to buy into the...

Seer Inc. Releases Financial Results for Third Quarter 2026

November 11, 2026 - 03:22

Seer Inc. Releases Financial Results for Third Quarter 2026

REDWOOD CITY, Calif., Nov. 10, 2026 -- Seer, Inc., a leader in proteomic insights, has shared its financial performance for the third quarter of 2026. The company reported a revenue of $4.0 million...

read all news
newsfieldsarchivecontact ussupport

Copyright © 2026 Credlx.com

Founded by: Knight Barrett

landingpicksconversationsabout usarticles
privacycookie policyterms